Eiger Biopharmaceuticals (NASDAQ:EIGR) Posts Earnings Results, Misses Expectations By $0.01 EPS

Eiger Biopharmaceuticals (NASDAQ:EIGR) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.76) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.01), Fidelity Earnings reports.

Shares of EIGR stock opened at $10.97 on Friday. The stock has a market cap of $275.02 million, a PE ratio of -2.87 and a beta of 1.02. The business has a 50-day simple moving average of $10.63 and a 200-day simple moving average of $10.76. The company has a quick ratio of 9.64, a current ratio of 9.64 and a debt-to-equity ratio of 0.36. Eiger Biopharmaceuticals has a 52-week low of $8.40 and a 52-week high of $15.33.

A number of brokerages have commented on EIGR. BidaskClub raised Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, October 30th. LADENBURG THALM/SH SH reissued a “buy” rating and issued a $28.00 price objective on shares of Eiger Biopharmaceuticals in a report on Monday, August 12th. Zacks Investment Research cut Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. Finally, ValuEngine cut Eiger Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $28.67.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Featured Story: Stocks at 52 Week High

Earnings History for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.